California Department of Public Health, Center for Infectious Diseases, Division of Communicable Disease Control, Tuberculosis Control Branch, Richmond, CA ; Current affiliation: California Department of Public Health, Center for Infectious Diseases, Division of Communicable Disease Control, Immunization Branch, Richmond, CA.
California Department of Public Health, Center for Infectious Diseases, Division of Communicable Disease Control, Tuberculosis Control Branch, Richmond, CA.
Public Health Rep. 2014 Mar-Apr;129(2):170-7. doi: 10.1177/003335491412900211.
National guidelines highlight the roles of early HIV diagnosis and effective comanagement for HIV and tuberculosis (TB) to prevent mortality and morbidity from HIV-related TB. We assessed HIV diagnosis timing and HIV/TB comanagement for California HIV/TB patients.
We reviewed and analyzed public health charts for California HIV/TB patients reported during 2008. HIV diagnoses fewer than three months before TB diagnosis were considered new HIV diagnoses. We determined the proportion of patients with new HIV diagnoses, risk factors for new HIV diagnoses, and proportion of patients receiving recommended CD4 cell count measurements, supervised TB therapy, and antiretroviral therapy (ART).
Of 130 HIV/TB patients, 51% had new HIV diagnoses. Foreign-born patients were more likely than U.S.-born patients to have new HIV diagnoses. Supervised TB therapy and CD4 cell count measurements followed national recommendations for 91% and 74% of patients, respectively. At least 73% of patients started ART before completing TB therapy. Compared with patients who had previous HIV diagnoses, patients with new HIV diagnoses started ART later and had lower CD4 cell counts and higher viral loads at TB diagnosis.
Although most HIV/TB patients received the recommended treatment, half had new HIV diagnoses. Compared with patients who had previous HIV diagnoses, patients with new HIV diagnoses had greater immunosuppression at TB diagnosis. A new diagnosis indicates that HIV could have been diagnosed earlier and ART or treatment for latent TB infection could have been initiated to prevent TB development.
国家指南强调了早期 HIV 诊断和 HIV 与结核病(TB)的有效共同管理,以预防与 HIV 相关的 TB 导致的死亡率和发病率。我们评估了加利福尼亚州 HIV/TB 患者的 HIV 诊断时机和 HIV/TB 共同管理。
我们回顾和分析了 2008 年报告的加利福尼亚州 HIV/TB 患者的公共卫生图表。HIV 诊断在 TB 诊断前少于三个月被认为是新的 HIV 诊断。我们确定了新的 HIV 诊断患者的比例、新的 HIV 诊断的风险因素,以及接受推荐的 CD4 细胞计数测量、监督 TB 治疗和抗逆转录病毒治疗(ART)的患者比例。
在 130 名 HIV/TB 患者中,有 51%的患者有新的 HIV 诊断。与美国本土出生的患者相比,外国出生的患者更有可能有新的 HIV 诊断。监督 TB 治疗和 CD4 细胞计数测量分别为 91%和 74%的患者遵循了国家建议。至少 73%的患者在完成 TB 治疗之前开始接受 ART。与有既往 HIV 诊断的患者相比,新诊断为 HIV 的患者开始接受 ART 的时间较晚,并且在 TB 诊断时 CD4 细胞计数较低,病毒载量较高。
尽管大多数 HIV/TB 患者接受了推荐的治疗,但有一半的患者有新的 HIV 诊断。与有既往 HIV 诊断的患者相比,新诊断为 HIV 的患者在 TB 诊断时免疫抑制更为严重。新的诊断表明 HIV 本可以更早诊断,ART 或潜伏性 TB 感染的治疗本可以更早开始,以预防 TB 的发生。